Posted by Michael Wonder on 01 Jan 2019
Adamis Pharmaceuticals submits new drug application to FDA for its naloxone pre-filled syringe
31 December 2018 - Adamis Pharmaceuticals today announced the submission of a new drug application to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe product candidate.
This injection is designed for the treatment of an opioid overdose. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
